MLTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller is pursuing a class action lawsuit against MoonLake Immunotherapeutics (MLTX) for alleged misleading statements, seeking investors with substantial losses to lead the suit.Summary
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who purchased the company’s stock during the class period. The lawsuit alleges that MoonLake made false and misleading statements regarding its drug candidate, sonelokimab (SLK), and its potential to compete with BIMZELX, a similar drug already approved by the FDA. Specifically, the complaint claims that MoonLake failed to disclose that SLK’s Nanobody structure would not provide a clinical advantage over BIMZELX, and that its tissue penetration would not translate to efficacy. Following the announcement of Phase 3 trial results on September 28, 2025, which showed SLK failed to demonstrate competitive efficacy, MoonLake’s stock price fell nearly 90%. Investors who suffered substantial losses are encouraged to apply to serve as lead plaintiff in the lawsuit by December 15, 2025. Robbins Geller is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024.
(Source：The AI Journal)